Purpose: To find out which treatment, neoadjuvant chemotherapy (NAC) or postoperative chemotherapy (PAC), can bring greater survival benefits to gastric cancer patients.
Methods: Pubmed, Embase and Cochrane Library databases were searched for randomized controlled trials （RCTs）about multidisciplinary treatment of resectable gastric cancer (NAC vs PAC, NAC + surgery vs surgery alone, and surgery alone vs surgery + PAC). Quality was assessed by collaboration recommendation in Cochrane. All outcomes were evaluated by odds ratio (OR) and 95% confidence interval (CI). Pairwise comparisons were conducted by R3.12 software. Aggregate Data Drug Information System (ADDIS software 1.16.5) was used to perform network meta-analysis.
Results: Simple meta-analysis showed NAC could bring more survival benefits than PAC for resectable gastric cancer. NAC was significantly better than PAC in 1-year (I2=0, p=0.4085, fixed effects model, OR=2.28, 95%CI: 1.27-4.04), 3-year (I2=0,p=0.6979，fixed effects model, OR=2.10, 95%CI: 1.09-4.03), and 5-year survival (I2=37.8%, p=0.2048，fixed effects model, OR=2.04, 95%CI: 1.03-4.06). Network meta-analysis showed NAC + surgery was better compared with surgery + PAC and surgery alone. NAC + surgery were significantly better than surgery + PAC and surgery alone in 1-year or 3-year survival. For 5-year survival, NAC + surgery were significantly better than surgery alone, but no significant difference was observed when compared with surgery + PAC. NAC + surgery ranked first in 1-year, 3-year and 5-year probability sequence diagram.
Conclusion: NAC brings greater survival benefits than PAC for patients with resectable gastric cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of a Prognostic Nomogram for Overall Survival in Gastric Cancer Patients Who Underwent Adjuvant Chemoradiotherapy.
J Gastrointest Cancer
January 2025
Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Purpose: The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.
Methods: We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method.
Lynch Syndrome: Similarities and Differences of Recommendations in Published Guidelines.
J Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Hepatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Background: In this review, we aimed to compare the recommendations for Lynch syndrome (LS).
Methods: We compared the LS's guidelines of different medical societies, including recommendations for cancer surveillance, aspirin treatment, and universal screening.
Results: Most guidelines for LS patients recommend intervals of 1-2 years for performing colonoscopy, though there is disagreement regarding the age to begin CRC screening (dependent on status as a MLH1/MSH2 or MSH6/PMS2 carrier).
The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with a strategy to ensure the safety of patients.
Mol Ther
January 2025
Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China; Shenzhen University-Haoshi Cell Therapy Institute, Shenzhen, China. Electronic address:
Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Claudin18.2 is highly expressed in PC tissue and could serve as a suitable target for CAR-T therapy.
View Article and Find Full Text PDFEvaluation of Plasma microRNA-222 as a Biomarker for Gastric Cancer.
J Clin Med
December 2024
Department of Surgery, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura 285-8741, Chiba, Japan.
The dysregulation of microRNAs (miRNAs) has been detected in patients with gastric cancer (GC), which inspired the use of miRNAs as a novel biomarker for GC. In this study, we investigated the previously reported miRNA dysfunction in cancer tissues as a potential plasma biomarker for GC using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). The published miRNA abnormalities were searched in the microRNA Cancer Association Database.
View Article and Find Full Text PDFGastric Intestinal Metaplasia in Children and Adolescents Is Reversible upon Reaching Adulthood-Results from a Long-Term Cohort Study.
Cancers (Basel)
January 2025
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Background/objectives: Gastric intestinal metaplasia (GIM) is considered an irreversible preneoplastic precursor for gastric adenocarcinoma in adults. However, its significance in children and the long-term outcome remain poorly understood.
Methods: All children diagnosed with GIM between 2000 and 2020 were identified at a large tertiary referral centre.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!